GMAB – Genmab A/S

Genmab A/S

GMAB

$30.06

Name : Genmab A/S

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $18,516,752,384.00

EPSttm : 2.28

Genmab A/S

$30.06

1.76%

$0.54

Float Short %

1.37

Margin Of Safety %

Put/Call OI Ratio

1.21

EPS Next Q Diff

-0.5

EPS Last/This Y

0.21

EPS This/Next Y

-0.43

Price

30.06

Target Price

37.42

Analyst Recom

1.71

Performance Q

3.44

Relative Volume

0.86

Beta

0.93

Ticker: GMAB

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-13	GMAB	33.88	0.27	12.47	5844
2026-01-14	GMAB	35.31	0.39	0.15	6379
2026-01-15	GMAB	33.88	0.40	4.31	6406
2026-01-16	GMAB	32.26	0.48	1.51	6795
2026-01-20	GMAB	31.32	0.61	4.39	5325
2026-01-21	GMAB	32.94	0.74	26.28	5731
2026-01-22	GMAB	33.11	0.88	0.81	6203
2026-01-23	GMAB	33.91	0.88	0.48	6265
2026-01-26	GMAB	33.48	0.89	11.43	6279
2026-01-27	GMAB	34.42	1.01	3.93	6700
2026-01-28	GMAB	32.94	1.28	0.02	8000
2026-01-29	GMAB	33.37	1.28	0.00	8022
2026-01-30	GMAB	32.62	1.25	0.10	8092
2026-02-02	GMAB	33.26	1.22	0.05	8217
2026-02-03	GMAB	33.04	1.22	0.01	8206
2026-02-04	GMAB	31.9	1.20	0.12	8265
2026-02-05	GMAB	30.98	1.21	0.00	8240
2026-02-06	GMAB	30.9	1.23	0.00	8206
2026-02-09	GMAB	30.86	1.22	0.02	8211
2026-02-10	GMAB	30.6	1.22	0.00	8233
2026-02-11	GMAB	30.05	1.21	0.00	8244
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-13	GMAB	33.87	-49.5	152.2	1.92
2026-01-14	GMAB	35.31	-49.5	258.7	1.92
2026-01-15	GMAB	33.87	-49.5	69.3	1.92
2026-01-16	GMAB	32.26	-49.5	50.2	1.92
2026-01-20	GMAB	31.33	-49.5	-24.5	1.92
2026-01-21	GMAB	32.95	-49.5	271.0	1.92
2026-01-22	GMAB	33.11	-48.2	160.5	1.92
2026-01-23	GMAB	33.88	-48.2	181.0	1.92
2026-01-26	GMAB	33.47	-49.7	154.7	1.92
2026-01-27	GMAB	34.42	-49.7	232.9	1.92
2026-01-28	GMAB	32.93	-49.7	90.2	1.92
2026-01-29	GMAB	33.37	-49.7	222.3	1.92
2026-01-30	GMAB	32.63	-49.7	154.1	1.92
2026-02-02	GMAB	33.27	-49.7	231.7	1.92
2026-02-03	GMAB	33.04	-49.7	103.0	1.92
2026-02-04	GMAB	31.90	-49.7	77.7	1.92
2026-02-05	GMAB	30.97	-49.7	113.7	1.92
2026-02-06	GMAB	30.92	-49.7	173.7	1.92
2026-02-09	GMAB	30.85	-49.7	157.8	1.92
2026-02-10	GMAB	30.60	-49.7	167.5	1.92
2026-02-11	GMAB	30.06	-49.7	116.3	1.92
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-13	GMAB	0	0.53	1.81
2026-01-14	GMAB	0	0.53	1.81
2026-01-15	GMAB	0	0.53	1.81
2026-01-16	GMAB	0	0.53	1.81
2026-01-20	GMAB	0	0.45	1.81
2026-01-21	GMAB	0	0.45	1.81
2026-01-22	GMAB	0	0.45	1.81
2026-01-23	GMAB	0	0.45	1.81
2026-01-26	GMAB	0	0.41	1.81
2026-01-27	GMAB	0	0.41	1.81
2026-01-28	GMAB	0	0.41	1.61
2026-01-29	GMAB	0	0.41	1.61
2026-01-30	GMAB	0	0.41	1.61
2026-02-02	GMAB	0	0.41	1.61
2026-02-03	GMAB	0	0.41	1.61
2026-02-04	GMAB	0	0.41	1.61
2026-02-05	GMAB	0	0.41	1.61
2026-02-06	GMAB	0	0.41	1.61
2026-02-09	GMAB	0	0.44	1.61
2026-02-10	GMAB	0	0.44	1.61
2026-02-11	GMAB	0	0.44	1.37
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.65

Avg. EPS Est. Current Quarter

0.42

Avg. EPS Est. Next Quarter

0.15

Insider Transactions

Institutional Transactions

0.44

Beta

0.93

Average Sales Estimate Current Quarter

6550

Average Sales Estimate Next Quarter

6015

Fair Value

41.01

Quality Score

100

Growth Score

Sentiment Score

Actual DrawDown %

38.8

Max Drawdown 5-Year %

-63.1

Target Price

37.42

P/E

12.76

Forward P/E

15.66

PEG

0.76

P/S

5.16

P/B

3.22

P/Free Cash Flow

14.83

EPS

2.35

Average EPS Est. Cur. Y

1.92

EPS Next Y. (Est.)

1.49

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

41.34

Relative Volume

0.86

Return on Equity vs Sector %

-2.7

Return on Equity vs Industry %

13.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

116.3

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 2681

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, Anthropic PBC, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

Novo Nordisk A/S

NVO

$48.74

Name : Novo Nordisk A/S

Sector : Healthcare

Industry: Drug Manufacturers - General

Mark. Cap: $216,732,991,488.00

EPSttm : 3.67

Novo Nordisk A/S

$48.74

0.77%

$0.38

Float Short %

0.94

Margin Of Safety %

Put/Call OI Ratio

0.84

EPS Next Q Diff

4.17

EPS Last/This Y

17.48

EPS This/Next Y

1.05

Price

48.73

Target Price

58.65

Analyst Recom

2.26

Performance Q

6.09

Relative Volume

0.55

Beta

0.68

Ticker: NVO

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-13	NVO	59.56	0.79	0.47	1560931
2026-01-14	NVO	58.9	0.79	0.43	1585092
2026-01-15	NVO	57.12	0.80	1.15	1606497
2026-01-16	NVO	62.32	0.84	0.42	1693378
2026-01-20	NVO	60.72	0.88	0.60	1328034
2026-01-21	NVO	59.32	0.84	0.64	1361008
2026-01-22	NVO	62.23	0.85	0.59	1422546
2026-01-23	NVO	62.27	0.87	0.35	1450815
2026-01-26	NVO	63.98	0.88	0.52	1371791
2026-01-27	NVO	62.82	0.87	0.58	1396499
2026-01-28	NVO	60.35	0.88	0.44	1409720
2026-01-29	NVO	59.33	0.88	1.23	1429014
2026-01-30	NVO	59.45	0.89	0.63	1450169
2026-02-02	NVO	58.94	0.84	0.80	1346822
2026-02-03	NVO	50.33	0.85	0.69	1372674
2026-02-04	NVO	47.23	0.88	0.63	1409799
2026-02-05	NVO	43.36	0.86	0.66	1469645
2026-02-06	NVO	47.68	0.80	0.73	1554469
2026-02-09	NVO	49.37	0.84	0.55	1474904
2026-02-10	NVO	49.1	0.84	0.39	1500076
2026-02-11	NVO	48.7	0.84	0.57	1520168
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-13	NVO	59.63	-8.3	-2122.6	23.03
2026-01-14	NVO	58.92	-8.3	-2556.0	23.03
2026-01-15	NVO	57.12	-8.3	-2882.1	23.03
2026-01-16	NVO	62.35	-8.3	-497.6	23.03
2026-01-20	NVO	60.67	-7.9	-2278.8	23.03
2026-01-21	NVO	59.33	-7.9	-2725.3	23.03
2026-01-22	NVO	62.22	-7.9	-1016.4	23.03
2026-01-23	NVO	62.24	-7.9	-2170.9	23.03
2026-01-26	NVO	63.99	-6.4	-2069.7	23.03
2026-01-27	NVO	62.89	-6.4	-2266.5	23.03
2026-01-28	NVO	60.34	-6.9	-2891.8	23.03
2026-01-29	NVO	59.33	-6.9	-2606.4	23.03
2026-01-30	NVO	59.44	-6.9	-2020.1	23.03
2026-02-02	NVO	58.97	-6.9	-2126.3	23.03
2026-02-03	NVO	50.35	-6.9	-5065.2	23.03
2026-02-04	NVO	47.25	-6.9	-2943.5	23.03
2026-02-05	NVO	43.34	-22.7	-52.4	22.37
2026-02-06	NVO	47.68	-22.7	3960.9	22.37
2026-02-09	NVO	49.37	-23.9	1824.9	21.51
2026-02-10	NVO	49.10	-24.4	-2394.3	21.12
2026-02-11	NVO	48.73	-24.4	-2743.2	21.12
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-13	NVO	0	-1.33	0.96
2026-01-14	NVO	0	-1.33	0.96
2026-01-15	NVO	0	-1.33	0.96
2026-01-16	NVO	0	-1.33	0.96
2026-01-20	NVO	0	-1.66	0.96
2026-01-21	NVO	0	-1.66	0.96
2026-01-22	NVO	0	-1.66	0.96
2026-01-23	NVO	0	-1.66	0.96
2026-01-26	NVO	0	-1.52	0.96
2026-01-27	NVO	0	-1.52	0.96
2026-01-28	NVO	0	-1.52	0.84
2026-01-29	NVO	0	-1.52	0.84
2026-01-30	NVO	0	-1.52	0.84
2026-02-02	NVO	0	-1.57	0.84
2026-02-03	NVO	0	-1.57	0.84
2026-02-04	NVO	0	-1.57	0.84
2026-02-05	NVO	0	-1.57	0.84
2026-02-06	NVO	0	-1.57	0.84
2026-02-09	NVO	0	-1.17	0.84
2026-02-10	NVO	0	-1.17	0.84
2026-02-11	NVO	0	-1.17	0.94
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

4.94

Avg. EPS Est. Next Quarter

5.17

Insider Transactions

Institutional Transactions

-1.17

Beta

0.68

Average Sales Estimate Current Quarter

74945

Average Sales Estimate Next Quarter

70920

Fair Value

51.55

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

67.1

Max Drawdown 5-Year %

-69.6

Target Price

58.65

P/E

14.05

Forward P/E

13.95

PEG

7.42

P/S

3.51

P/B

7.1

P/Free Cash Flow

18.35

EPS

3.47

Average EPS Est. Cur. Y

21.12

EPS Next Y. (Est.)

22.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

33.03

Relative Volume

0.55

Return on Equity vs Sector %

24.9

Return on Equity vs Industry %

16.6

EPS 1 7Days Diff

-1.2

EPS 1 30Days Diff

-0.56

EBIT Estimation

-2743.2

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 68794

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

Ascendis Pharma A/S

ASND

$221.49

Name : Ascendis Pharma A/S

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $13,532,631,040.00

EPSttm : -4.53

Ascendis Pharma A/S

$221.49

1.14%

$2.56

Float Short %

4.79

Margin Of Safety %

Put/Call OI Ratio

0.34

EPS Next Q Diff

1.62

EPS Last/This Y

4.36

EPS This/Next Y

7.26

Price

221.1

Target Price

274.44

Analyst Recom

1.22

Performance Q

Relative Volume

1.36

Beta

0.43

Ticker: ASND

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-13	ASND	214.96	0.27	0.05	19848
2026-01-14	ASND	217.5	0.26	0.47	20173
2026-01-15	ASND	215.25	0.26	0.00	20269
2026-01-16	ASND	205.69	0.27	2.95	19639
2026-01-20	ASND	215.28	0.28	0.12	12088
2026-01-21	ASND	216.78	0.31	0.72	12695
2026-01-22	ASND	228.67	0.31	0.42	12727
2026-01-23	ASND	235.41	0.32	0.44	13126
2026-01-26	ASND	233.82	0.33	0.02	13992
2026-01-27	ASND	238.72	0.32	0.10	14323
2026-01-28	ASND	222.43	0.32	0.38	14393
2026-01-29	ASND	223.6	0.33	0.17	14642
2026-01-30	ASND	225.99	0.34	1.15	14599
2026-02-02	ASND	223.37	0.34	0.29	14610
2026-02-03	ASND	224.78	0.34	1.07	14614
2026-02-04	ASND	219.67	0.35	0.29	15001
2026-02-05	ASND	217.7	0.35	1.10	15006
2026-02-06	ASND	222.23	0.35	2.52	15011
2026-02-09	ASND	222.47	0.34	0.10	14942
2026-02-10	ASND	224.22	0.34	0.67	14988
2026-02-11	ASND	221.43	0.34	0.24	15000
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-13	ASND	215.04	79.0	388.0	-3.22
2026-01-14	ASND	217.44	72.2	383.9	-3.22
2026-01-15	ASND	215.27	72.2	379.4	-3.22
2026-01-16	ASND	205.76	70.0	372.5	-3.22
2026-01-20	ASND	215.45	63.9	391.1	-3.22
2026-01-21	ASND	216.76	58.1	382.2	-3.22
2026-01-22	ASND	228.64	58.1	392.6	-3.22
2026-01-23	ASND	235.31	56.7	387.1	-3.22
2026-01-26	ASND	233.81	56.7	379.6	-3.22
2026-01-27	ASND	238.77	56.7	385.6	-3.22
2026-01-28	ASND	222.45	56.7	366.7	-3.22
2026-01-29	ASND	223.84	62.1	382.5	-3.22
2026-01-30	ASND	225.80	62.1	383.1	-3.22
2026-02-02	ASND	223.34	61.7	378.9	-3.22
2026-02-03	ASND	224.55	61.7	385.3	-3.22
2026-02-04	ASND	219.95	61.7	-	-3.22
2026-02-05	ASND	217.60	61.7	-	-3.22
2026-02-06	ASND	222.26	61.7	-	-3.22
2026-02-09	ASND	222.07	61.7	-	-3.22
2026-02-10	ASND	224.15	61.7	-	-3.22
2026-02-11	ASND	221.10	61.7	-	-3.22
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-13	ASND	0.00	1.78	5.71
2026-01-14	ASND	0.00	1.78	5.71
2026-01-15	ASND	0.00	1.78	5.71
2026-01-16	ASND	0.00	1.78	5.71
2026-01-20	ASND	0.00	1.60	5.71
2026-01-21	ASND	0.00	1.60	5.71
2026-01-22	ASND	0.00	1.60	5.71
2026-01-23	ASND	0.00	1.60	5.71
2026-01-26	ASND	0.00	2.05	5.71
2026-01-27	ASND	0.00	2.05	5.71
2026-01-28	ASND	0.00	2.05	5.23
2026-01-29	ASND	0.00	2.05	5.23
2026-01-30	ASND	0.00	2.05	5.23
2026-02-02	ASND	0.00	2.04	5.23
2026-02-03	ASND	0.00	2.04	5.23
2026-02-04	ASND	0.00	2.04	5.23
2026-02-05	ASND	0.00	2.04	5.23
2026-02-06	ASND	0.00	2.04	5.23
2026-02-09	ASND	0.00	1.01	5.23
2026-02-10	ASND	0.00	1.01	5.23
2026-02-11	ASND	0.00	1.01	4.79
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.17

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

0.45

Insider Transactions

Institutional Transactions

1.01

Beta

0.43

Average Sales Estimate Current Quarter

245

Average Sales Estimate Next Quarter

281

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

8.6

Max Drawdown 5-Year %

-60.5

Target Price

274.44

P/E

Forward P/E

48.88

PEG

P/S

18.78

P/B

P/Free Cash Flow

EPS

-4.25

Average EPS Est. Cur. Y

-3.22

EPS Next Y. (Est.)

4.04

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-35.52

Relative Volume

1.36

Return on Equity vs Sector %

106

Return on Equity vs Industry %

122.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.17

EBIT Estimation

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1017

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y